News | May 30, 2025
Procter & Gamble Hygiene and Health Care posts Q3 FY25 PAT at Rs. 156 Cr
The company also announced results for the third quarter, reporting sales at Rs. 992 crore, flat versus year ago
The company also announced results for the third quarter, reporting sales at Rs. 992 crore, flat versus year ago
Annual EBITDA margin expands by 170 basis points
MANEUVER met all five key secondary endpoints, with statistically significant and clinically meaningful improvements in pain, stiffness, range of motion, physical function, and decrease in tumor volume
This is specifically for the evaluation of medicines that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, prevention, or diagnosis of a serious condition
Usnoflast has previously also received ‘Orphan Drug Designation (ODD)’ from the USFDA
Adjusted EBITDA positive at Rs. 3.1 crore despite investments in marketing, talent hiring and technology over the year
Campaign empowers women to prioritise their health through thought provoking films, influencer-led campaigns, scientific and medical podcasts, survivor experiences, and digital awareness
Akums invested Rs. 272 crore in capital expenditure during FY25
The company expects meaningful revenue contribution from this long-term agreement
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
